Tamarack data reveal vobra-duo’s toxicity, and wipe out the past six month’s share price gains.
ApexOnco Front Page
Recent articles
But the group’s attempt to join Janux at the high altar of masking technology falls flat.
A tumour-agnostic label for Enhertu leads April’s US oncology approvals.
A phase 2 head and neck trial missed its primary endpoint, but the group is taking heart from survival data.
The company’s long-delayed pivotal trial is hit by a stronger-than-expected placebo performance.
Hutchmed starts phase 1 with a project in a field where Syndax and Kura have so far been the main players.
The new developer will focus on the crowded KRAS space and PI3Kα/AKT inhibition, which has been hit by toxicity issues.
AstraZeneca celebrates success in the Echo trial in mantle cell lymphoma, but watch out for BeiGene.
